Clinical Trial Update: Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating peginterferon alfa-2a for chronic hepatitis B patients who failed antiviral therapy; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Peginterferon alfa-2a (40 kDa) (pegylated interferon alfa-2a)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Chronic Hepatitis B | Phase 4 | Status: COMPLETED